US 2490813A
· Hughes et al.
· 1949
[cited by applicant]
US 3299078A
· Pachter
· 1967
[cited by applicant]
US 3813392A
· Sellstedt et al.
· 1974
[cited by applicant]
US 3914421A
· Rajagopalan
· 1975
[cited by applicant]
US 4001263A
· Plattner et al.
· 1977
[cited by applicant]
US 4115577A
· Rajagopalan
· 1978
[cited by applicant]
US 4183936A
· Rajagopalan
· 1980
[cited by applicant]
US 4219550A
· Rajagopalan
· 1980
[cited by applicant]
US 4238607A
· Rajagopalan
· 1980
[cited by applicant]
US 4389330A
· Tice et al.
· 1983
[cited by applicant]
US 4522944A
· Doria et al.
· 1985
[cited by applicant]
US 4530840A
· Tice et al.
· 1985
[cited by applicant]
US 4767628A
· Hutchinson
· 1988
[cited by applicant]
US 4971971A
· Tokunaga et al.
· 1990
[cited by applicant]
US 4985432A
· Tokunaga et al.
· 1991
[cited by applicant]
US 5004602A
· Hutchinson
· 1991
[cited by applicant]
US 5114976A
· Norden
· 1992
[cited by applicant]
US 5151419A
· Perenyi et al.
· 1992
[cited by applicant]
US 5538739A
· Bodmer et al.
· 1996
[cited by applicant]
US 5648539A
· Goodbrand
· 1997
[cited by applicant]
US 5648542A
· Goodbrand et al.
· 1997
[cited by applicant]
US 5654482A
· Goodbrand
· 1997
[cited by applicant]
US 5705697A
· Goodbrand et al.
· 1998
[cited by applicant]
US 5723669A
· Goodbrand et al.
· 1998
[cited by applicant]
US 5723671A
· Goodbrand et al.
· 1998
[cited by applicant]
US 5834493A
· Quintero et al.
· 1998
[cited by applicant]
US 5902901A
· Goodbrand et al.
· 1999
[cited by applicant]
US 5922338A
· Brich et al.
· 1999
[cited by applicant]
US 6043370A
· Kubo et al.
· 2000
[cited by applicant]
US 6110921A
· Mesens et al.
· 2000
[cited by applicant]
US 6323366B1
· Wolfe et al.
· 2001
[cited by applicant]
US 6407092B1
· Hester et al.
· 2002
[cited by applicant]
US 6448243B1
· Kitazawa et al.
· 2002
[cited by applicant]
US 6541639B2
· Zhou et al.
· 2003
[cited by applicant]
US 6544559B2
· Mesens et al.
· 2003
[cited by applicant]
US 6548493B1
· Robichaud et al.
· 2003
[cited by applicant]
US 6552017B1
· Robichaud et al.
· 2003
[cited by applicant]
US 6699852B2
· Robichaud et al.
· 2004
[cited by applicant]
US 6713471B1
· Robichaud et al.
· 2004
[cited by applicant]
US 6762329B2
· Marcoux et al.
· 2004
[cited by applicant]
US 6849619B2
· Robichaud et al.
· 2005
[cited by applicant]
US 6849640B2
· Ennis et al.
· 2005
[cited by applicant]
US 6929803B2
· Wong et al.
· 2005
[cited by applicant]
US 7071186B2
· Robichaud et al.
· 2006
[cited by applicant]
US 7081455B2
· Robichaud et al.
· 2006
[cited by applicant]
US 7109339B2
· Lee et al.
· 2006
[cited by applicant]
US 7183282B2
· Robichaud et al.
· 2007
[cited by applicant]
US 7223870B2
· Ghosh et al.
· 2007
[cited by applicant]
US RE39679E
· Robichaud et al.
· 2007
[cited by applicant]
US RE39680E
· Robichaud et al.
· 2007
[cited by applicant]
US 7238690B2
· Robichaud et al.
· 2007
[cited by applicant]
US 7244734B2
· Bakker et al.
· 2007
[cited by applicant]
US 7375226B2
· Jolidon et al.
· 2008
[cited by applicant]
US 7462641B2
· Igo et al.
· 2008
[cited by applicant]
US 7592454B2
· Lee et al.
· 2009
[cited by applicant]
US 7614727B2
· Hori
· 2009
[cited by applicant]
US 7645752B2
· McDevitt et al.
· 2010
[cited by applicant]
US 7998971B2
· Barlow et al.
· 2011
[cited by applicant]
US 8309722B2
· Tomesch et al.
· 2012
[cited by applicant]
US 8309772B2
· Weiner et al.
· 2012
[cited by applicant]
US 8461148B2
· Hollander
· 2013
[cited by applicant]
US 8598119B2
· Mates et al.
· 2013
[cited by applicant]
US 8648077B2
· Tomesch et al.
· 2014
[cited by applicant]
US 8779139B2
· Tomesch et al.
· 2014
[cited by applicant]
US 8791138B2
· Seeman et al.
· 2014
[cited by applicant]
US 8993572B2
· Mates et al.
· 2015
[cited by applicant]
US 9168258B2
· Mates et al.
· 2015
[cited by applicant]
US 9199995B2
· Tomesch et al.
· 2015
[cited by applicant]
US 9315504B2
· Tomesch et al.
· 2016
[cited by applicant]
US 9371324B2
· Mates et al.
· 2016
[cited by applicant]
US 9393192B2
· Yam et al.
· 2016
[cited by applicant]
US 9427412B2
· Bryson et al.
· 2016
[cited by applicant]
US 9428506B2
· Mates et al.
· 2016
[cited by applicant]
US 9567327B2
· Xiong et al.
· 2017
[cited by applicant]
US 9586960B2
· Tomesch et al.
· 2017
[cited by applicant]
US 9616061B2
· Mates et al.
· 2017
[cited by applicant]
US 9708322B2
· Li et al.
· 2017
[cited by applicant]
US 9745300B2
· Mates et al.
· 2017
[cited by applicant]
US 9751883B2
· Tomesch et al.
· 2017
[cited by applicant]
US 9956227B2
· Vanover et al.
· 2018
[cited by applicant]
US 20040092534A1
· Yam et al.
· 2004
[cited by applicant]
US 20040127482A1
· Robichaud et al.
· 2004
[cited by applicant]
US 20040142970A1
· Chung et al.
· 2004
[cited by applicant]
US 20050166771A1
· Gygi et al.
· 2005
[cited by applicant]
US 20050182749A1
· Matsui
· 2005
[cited by applicant]
US 20050222209A1
· Zeldis et al.
· 2005
[cited by applicant]
US 20060205787A1
· Muller et al.
· 2006
[cited by applicant]
US 20080069885A1
· Mesens et al.
· 2008
[cited by applicant]
US 20080132552A1
· Kleinman et al.
· 2008
[cited by applicant]
US 20080280941A1
· Lourtie
· 2008
[cited by applicant]
US 20090076159A1
· Czarnik
· 2009
[cited by applicant]
US 20110269777A1
· Bachurin et al.
· 2011
[cited by applicant]
US 20150080404A1
· Mates et al.
· 2015
[cited by applicant]
GB 1476087
· 1977
[cited by applicant]
WO WO2000064899
· 2000
[cited by applicant]
WO WO2000077001
· 2000
[cited by applicant]
WO WO2000077002
· 2000
[cited by applicant]
WO WO2000077010
· 2000
[cited by applicant]
WO WO2008112280
· 2008
[cited by applicant]
WO WO2009114181
· 2009
[cited by applicant]
WO WO2009145900
· 2009
[cited by applicant]
WO WO2011084846
· 2011
[cited by applicant]
WO WO2011133224
· 2011
[cited by applicant]
WO WO2013155504
· 2013
[cited by applicant]
WO WO2013155505
· 2013
[cited by applicant]
WO WO2013155506
· 2013
[cited by applicant]
WO WO2014145192
· 2014
[cited by applicant]
WO WO2015085004
· 2015
[cited by applicant]
WO WO2015154025
· 2015
[cited by applicant]
WO WO2015154030
· 2015
[cited by applicant]
WO WO2015191554
· 2015
[cited by applicant]
WO WO2017165755
· 2017
[cited by applicant]
WO WO2018106916
· 2018
[cited by applicant]
Aiken, C., “An Overview of Atypical Antipsychotics for Bipolar Depression,” published on Jan. 3, 2020 at https://www.psychiatrictimes.com/view/overview-atypical-antipsychotics-bipolar-depression, 11 pages.
[cited by applicant]
Alvir et al., “Clozapine-Induced Agranulocytosis,”
[cited by applicant]
Angst et al. “Prevalence and Characteristics of Undiagnosed Bipolar Disorders in Patients With a Major Depressive Episode”, Arch Gen Psychiatry, vol. 68, No. 8, p. 701-709, (2011).
[cited by applicant]
Balbach et al., “Pharmaceutical evaluation of early development candidates ‘the 100 mg-approach’”,
[cited by applicant]
Barman et al., “Newer Antipsychotics: Brexpiprazole, Cariprazine, and Lumateperone: A Pledge or Another Unkept Promise?,” World J. Psychiatr., vol. 11, No. 12, p. 1228-38 (2021).
[cited by applicant]
Bastin et al., “Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities”,
[cited by applicant]
Bennett et al., “Cecil Textbook of Medicine,” 20th Edition, vol. 1, pp. 1004-1010, (1996).
[cited by applicant]
Bowman et al., “Colloidal Dispersions,” Remington Essentials of Pharmaceutics, Chapter 20, pp. 343-370 (2012).
[cited by applicant]
Bremner et al., “Neuroimaging of Posttraumatic Stress Disorder”,
[cited by applicant]
Bryan-Lluka et al., “Potencies of Haloperidol Metabolites as Inhibitors of the Human Noradrenaline, Dopamine and Serotonin Transporters in Transfected COS-7 Cells”,
[cited by applicant]
Byrn et al., “Pharmaceutical Solids: A Strategic Approach to Regulatory Considerations,”
[cited by applicant]
Caira, M.R., “Crystalline Polymorphism of Organic Compounds,”
[cited by applicant]
Correll et al., “Efficacy and Safety of Lumateperone for Treatment of Schizophrenia A Randomized Clinical Trial,” JAMA Psychiatry, vol. 77, No. 4, p. 349-358 (2020).
[cited by applicant]
Coyle et al., “Beyond the Dopamine Receptor: Novel Therapeutic Targets for Treating Schizophrenia,” Dialogues Clin. Neurosci., vol. 12, No. 3, p. 359-382 (2010).
[cited by applicant]
Darmani et al., “Do Functional Relationships Exist Between 5-HT
[cited by applicant]
Davis et al., “ITI-007 in the Treatment of Schizophrenia: From Novel Pharmacology to Clinical Outcomes,”
[cited by applicant]
Del-Monte et al., “Nonverbal Expressive Behaviour in Schizophrenia and Social Phobia,” Psychiatry Res., vol. 210, p. 29-35 (2013).
[cited by applicant]
Docherty et al., “Effect of Aripiprazole Versus Haloperidol on PANSS Prosocial Items in Early-Episode Patients with Schizophrenia,” Schizophrenia Res., vol. 120, p. 199-203 (2010).
[cited by applicant]
Edinoff et al., “Lumateperone for the Treatment of Schizophrenia,” Psychopharmacology Bulletin, vol. 50, No. 4, p. 32-59 (2020).
[cited by applicant]
Ellenbroek et al., “Animal Models for the Negative Symptoms of Schizophrenia,” Behavioural Pharmacology, vol. 11, pp. 223-233, (2000).
[cited by applicant]
Fawcett, J., “Posttraumatic Stress Disorder, Stress, and Happiness”,
[cited by applicant]
Fletcher et al., “Perceiving is Believing: A Bayesian Approach to Explaining the Positive Symptoms of Schizophrenia,” Nature Reviews/Neuroscience, vol. 10, pp. 48-58, (2009).
[cited by applicant]
Foster et al., “Acetylcholinesterase inhibitors reduce spreading activation in dementia,”
[cited by applicant]
Foster et al., “Emerging Approaches for Treatment of Schizophrenia: Modulation of Cholinergic Signaling,” Discov. Med., vol. 14, No. 79, p. 413-420 (2012).
[cited by applicant]
Friedman, M.J.., “Current and Future Drug Treatment for Posttraumatic Stress Disorder Patients”,
[cited by applicant]
Gramigna, J, “Lumateperone Safe, Effective for Depressive Symptoms Among Patients with Bipolar Disorders,” American Society of Clinical Psychopharmacology Annual Meeting, Jun. 2, 2020, 3 pages.
[cited by applicant]
Grant, D., “Theory and Origin and Polymorphism”,
[cited by applicant]
Guillory, J.K., “Generation of Polymorphs, Hydrates, Solvates, and Amorphous Solids”,
[cited by applicant]
Hackam et al., “Translation of Research Evidence From Animals to Humans,” JAMA, vol. 296(14): 1731-1732 (2006).
[cited by applicant]
Harbert et al., “Neuroleptic Activity in 5-Aryltetrahydro-y-carbolines”,
[cited by applicant]
Harvey, “Ziprasidone and Cognition: The Evolving Story,” J. Clin. Psychiatry, vol. 64, No. s19, p. 33-39 (2003).
[cited by applicant]
Harvey et al., “Serotonin and Stress: Protective or Malevolent Actions in the Biobehavioral Response to Repeated Trauma?,”
[cited by applicant]
Haynes et al., “Occurrence of Pharmaceutically Acceptable Anions and Cations in the Cambridge Structural Database”,
[cited by applicant]
Helfer et al., “Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis,” Am. J. Psychiatry, vol. 173, No. 9, p. 876-886 (2016).
[cited by applicant]
Hlavinka, E., “Schizophrenia Tx Eases Depression in Bipolar Disorder: Lumateperone Offers Greater Rate of Response, Remission versus Placebo,” Medpage Today, 7 pages, (2020); https://www.medpagetoday.com/meetingcoverage…
[cited by applicant]
Howes et al., “Glutamate and Dopamine in Schizophrenia: An Update for the 21
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2013/036514 issued Oct. 14, 2014.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2008/003340, mailed Aug. 8, 2008, 3 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2009/001608, mailed Apr. 27, 2009, 3 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2009/003261, mailed Jul. 16, 2009.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2011/00719, mailed Jul. 5, 2011, 3 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2013/036515, mailed Aug. 13, 2013, 3 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2013/036514, mailed Aug. 16, 2013, 3 pages.
[cited by applicant]
International Search Report issued in International Application No. PCT/US2013/036512, mailed Aug. 19, 2013, 4 pages.
[cited by applicant]
International Search Report for International Application No. PCT/US2014/29914, mailed Aug. 12, 2014, 3 pages.
[cited by applicant]
Izrayelit, L., “Schizoaffective Disorder and PTSD Successfully Treated With Olanzapine and Supportive Psychotherapy”, Psychiatric Annals Journal, vol. 28, No. 8, pp. 424-426, (1998).
[cited by applicant]
Jain et al., “Polymorphism in Pharmacy”,
[cited by applicant]
Jordan, “Tamoxifen: A Most Unlikely Pioneering Medicine,” Nature Reviews, vol. 2: 205-213 (2003).
[cited by applicant]
Kahn et al., “Residual Symptoms of Schiziphrenia. What are Realistic Treatment Goals? Lingering Symptoms Require you to Evaluate Pharmacotherapy and Offer Psychosocial Interventions,”
[cited by applicant]
Kay et al., “The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia,”
[cited by applicant]
Kendrick, “The Newer, ‘Atypical’ Antipsychotic Drugs—Their Development and Current Therapeutic Use,” British J. General Practice, vol. 49, p. 745-749 (1999).
[cited by applicant]
Kessler et al., “Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication,”
[cited by applicant]
Khorana et al., “Gamma-Carbolines: Binding at 5-HT5A Serotonin Receptors,”
[cited by applicant]
Koppel et al., “Optimal Treatment of Alzheimer's Disease Psychosis: Challenges and Solutions,”
[cited by applicant]
Krystal et al., “Adjunctive Risperidone Treatment for Antidepressant- Resistant Symptoms of Chronic Military Service-Related PTSD: A Randomized Trial,” JAMA, vol. 306, No. 5, pp. 493-502, (2011).
[cited by applicant]
Lammers, et al., “Risperidone Long-acting Injection in Schizophrenia Spectrum Illnesses Compared to First Generation Depot Antipsychotics in an Outpatient Setting in Canada,” BMC Psychiatry, vol. 13, No. 155, 9 pages, (…
[cited by applicant]
Lebert et al., “Trazodone in Fronto-Temporal Dementia,”
[cited by applicant]
Lee et al. “Novel, Highly Potent, Selective 5-HT
[cited by applicant]
Li et al., “Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders,”
[cited by applicant]
Lieberman et al., “ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial,”
[cited by applicant]
Lin et al., “Dosage and Duration of Antipsychotic Treatment in Demented Outpatients with Agitation or Psychosis,”
[cited by applicant]
Lindström et al., “Principal Component Analysis of the Swedish Version of the Positive and Negative Syndrome Scale for Schizophrenia,” Nord. J. Psychiatry, vol. 47, No. 4, p. 257-263 (1993).
[cited by applicant]
Lipschitz et al., “Childhood Posttraumatic Stress Disorder: A Review of Neurobiologic Sequelae,”
[cited by applicant]
Liriano et al. “Ketamine as treatment for post-traumatic stress disorder: a review.”
[cited by applicant]
Lopez et al., “Psychiatric Symptoms Vary with the Severity of Dementia in Probably Alzheimer's Disease,”
[cited by applicant]
Madhusoodanan et al., “Pharmacological Management of Behavioral Symptoms Associated with Dementia,”
[cited by applicant]
Makadia et al., “Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier,” Polymers (Basel), vol. 3, No. 3, pp. 1377-1397, (2011).
[cited by applicant]
Marek et al. Synergistic Action of 5-HT2A Antagonists and Selective Serotonin Reuptake Inhibitors in Neuropsychiatric Disorders. Neuropsychopharmacology, 2003. vol. 28, pp. 402-412. (2003).
[cited by applicant]
Mass et al., “Psychopathological Syndromes of Schizophrenia: Evaluation of the Dimensional Structure of the Positive and Negative Syndrome Scale,” Schizophrenia Bull., vol. 26, No. 1, p. 167-177 (2000).
[cited by applicant]
McConnell et al., “Modified-Release Oral Drug Delivery,” Aulton's Pharmaceutics, Chapter 31, pp. 550-565 (2013).
[cited by applicant]
Medisorb Fact Sheet in Medisorb Microspheres Technology (Jan. 2009) at https://static.secure.website/wscfus/6472891/uploads/Medisorb.pdf (retrieved from the internet May 18, 2020) (2009).
[cited by applicant]
Mohamed et al., “Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: Diagnostic- and Symptom-guided Drug Selection,”
[cited by applicant]
Möller et al., “Pharmacological Treatment of Negative Symptoms in Schizophrenia,” Eur. Arch. Psychiatry Clin. Neurosci., vol. 265, p. 567-578 (2015).
[cited by applicant]
Morgan et al., “Acoustic Startle in Individuals With Posttraumatic Stress Disorder,”
[cited by applicant]
Mueller et al., “Detection of Depression in Acute Schizophrenia: Sensitivity and Specificity of 2 Standard Observer Rating Scales,” Can J Psychiatry, vol. 51, No. 6, pp. 387-392, (2006).
[cited by applicant]
Newman et al., “Solid-state Analysis of the Active Pharmaceutical Ingredient in Drug Products,”
[cited by applicant]
Noble et al., “The Opiod Receptors as Targets for Drug Abuse Medication,”
[cited by applicant]
Palanisamy, M. et al., “Cellulose-Based Matrix Microspheres of Prednisolone Inclusion Complex; Preparation and Characterization.” American Association of Pharmaceutical Scientists PharmSciTech, vol. 12, No. 1, pp. 388-4…
[cited by applicant]
Perlis et al., “Clinical Features of Bipolar Depression Versus Major Depressive Disorder in Large Multicenter Trials”, Am J Psychiatry, vol. 163, p. 225-231, (2006).
[cited by applicant]
Pieniaszek et al., “Moricizine Bioavailability via Simultaneous Dual, Stable Isotope Administration: Bioequivalence Implications,”
[cited by applicant]
Pine et al., “Dopamine, Time, and Impulsivity in Humans,”
[cited by applicant]
Pond et al., “Stereospecific Reduction of Haloperidol in Human Tissues,”
[cited by applicant]
Rackova et al., “Free Radical Scavenging and Antioxidant Activities of Substituted Hexahydropyridoindoles. Quantitative Structure-Activity Relationships.”
[cited by applicant]
Rainer, M.K., “Risperidone Long-acting Injection: A Review of its Long Term Safety and Efficacy,”
[cited by applicant]
Rummel et al., “Antidepressants as Add-on Treatment to Antipsychotics for People with Schizophrenia and Pronounced Negative Symptoms: A Systematic Review of Randomized Trials,” Schizophrenia Res., vol. 80, p. 85-97 (200…
[cited by applicant]
Rye (Sleep Disorders and Parkinson's Disease, 2000, accessed online http://www.waparkinsons.org/edu_research/articles/Sleep_Disorders.html), 2 pages.
[cited by applicant]
Savjani et al., “Drug Solubility: Importance and Enhancement Techniques,”
[cited by applicant]
Schennach et al., “What Are Residual Symptoms in Schizophrenia Spectrum Disorder? Clinical Description and 1-year Persistence Within a Naturalistic Trial,”
[cited by applicant]
“Securities,”
[cited by applicant]
Seishinkei Shi, vol. 110, No. 7, pp. 557-584, (2008); Partial English translation only.
[cited by applicant]
Sepehry et al., “Selective Serotonin Reuptake Inhibitor (SSRI) Add-On Therapy for the Negative Symptoms of Schizophrenia: A Meta-Analysis,” J. Clin. Psychiatry, vol. 68, No. 4, p. 604-610 (2007).
[cited by applicant]
Sigel et al., “Tenary Complexes in Solution,”
[cited by applicant]
Silver et al., “Multifunctional Pharmacotherapy: What Can We Learn from Study of Selective Serotonin Reuptake Inhibitor Augmentation of Antipsychotics in Negative-Symptom Schizophrenia?,” Neurotherapeutics, vol. 6, p. 8…
[cited by applicant]
Singh et al., “Efficacy of Antidepressants in Treating the Negative Symptoms of Chronic Schizophrenia: Meta-Analysis,” The British Journal of Psychiatry, vol. 197, p. 174-179 (2010).
[cited by applicant]
Singhal et al., “Drug Polymorphism and Dosage Form Design: A Practical Perspective,”
[cited by applicant]
Skoog et al.,
[cited by applicant]
Smith et al., “Oxford Dictionary of Biochemistry and Molecular Biology”,
[cited by applicant]
Smith et al., “Schizophrenia (Maintenance Treatment),” Clinical Evidence, 04: 1007 (2009).
[cited by applicant]
Snyder et al., “Functional Profile of a Novel Modulator of Serotonin, Dopamine, and Glutamate Neurotransmission,”
[cited by applicant]
Southwick et al., “Neuroendocrine Alterations in Posttraumatic Stress Disorder,”
[cited by applicant]
Taragano et al., “A Double-Blind, Randomized, Fixed-Dose Trial of Fluoxetine vs. Amitriptyline in the Treatment of Major Depression Complicating Alzheimer's Disease,”
[cited by applicant]
Tariot et al., “Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil: A Randomized Controlled Trail,”
[cited by applicant]
Tohen et al., “Efficacy of Olanzapine and Olanzapine-Fluoxetine Combination in the Treatment of Bipolar I Depression,” Arch Gen Psychiatry, vol. 60, pp. 1079-1088, (2003).
[cited by applicant]
Vanover et al., Abstracts of the 13
[cited by applicant]
Vanover et al., “ITI-007: A Novel Therapy for the Treatment of Schizophrenia and Related Psychoses,” International Clinical Psychopharamcology, vol. 26, e56, 1 page, (2011).
[cited by applicant]
Vanover et al., “Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia,”
[cited by applicant]
Vanover et al., “A Novel Approach to Address an Unmet Need in the Treatment of Schizophrenia and Depression: Lumateperone, an Innovative Modulator of Dopamine, Serotonin, and Glutamate,” Abstract presented at the Americ…
[cited by applicant]
Vyas et al., “An Evaluation of Lumateperone Tosylate for the Treatment of Schizophrenia,” Expert Opinion on Pharmacotherapy, vol. 21, No. 2, pp. 139-145, (2020); https://doi.org/10.1080/14656566.2019.1695778.
[cited by applicant]
Wennogle et al., “Activation of NMDA and AMPA Receptors by Lumateperone (ITI-007): Implications for Antidepressant Activity,” Abstract presented at the 2017 Collegium Internationale Neuro-Psychopharmacologicum (CINP) Th…
[cited by applicant]
Weschules et al., “Acetylcholinesterase Inhibitor and N-Methyl-D-Aspartic Acid Receptor Antagonist Use among Hospice Enrollees with a Primary Diagnosis of Dementia,”
[cited by applicant]
Wiese, M., “Dsc Detection of Polymorphism in Pharmaceutical Anhdrous Dexamethasone Acetate,”
[cited by applicant]
Written Opinion of the International Searching Authority for International Application No. PCT/US2013/036514 mailed Aug. 16, 2013, 4 pages.
[cited by applicant]
Yudofsky et al., “Propranolol in the Treatment of Rage and Violent Behavior in Patients with Chronic Brain Syndromes,”
[cited by applicant]
Zhang et al., “The Role of Serotonin 5-HT2A Receptors in Memory and Cognition,”
[cited by applicant]
Zhang et al., “Alterations of Amplitude of Low-Frequency Fluctuation in Treatment-Resistant Versus Non-Treatment-Resistant Depression Patients,” Neuropsychiatric Disease and Treatment, vol. 2019, No. 15, p. 2119-2128 (2…
[cited by applicant]
Press Release, “Intra-Cellular Therapies Announces Additional Results from Phase I/II Clinical Trail for ITI-007 in Healthy Geriatric Subjects and Patients With Dementia,” Intra-Cellular Therapies, Press Release Date: N…
[cited by applicant]
Su et al., “Effects of Formulation Parameters on Encapsulation Efficiency and Release Behavior of Risperidone Poly(D,L-lactide-co-glycolide) Microsphere,” Chem Pharm Bull., vol. 57, No. 11, p. 1251-1256, (2009).
[cited by applicant]